Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox

por Oh, David Y., Fong, Lawrence
Publicado 2021

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

por Hagihara, Katsunobu, Chan, Stephen, Zhang, Li, Oh, David Y., Wei, Xiao X., Simko, Jeffry, Fong, Lawrence
Publicado 2018

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

por Cham, Jason, Zhang, Li, Kwek, Serena, Paciorek, Alan, He, Tao, Fong, Grant, Oh, David Y, Fong, Lawrence
Publicado 2020

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients

por Naidus, Elliot, Bouquet, Jerome, Oh, David Y., Looney, Timothy J., Yang, Hai, Fong, Lawrence, Standifer, Nathan E., Zhang, Li
Publicado 2021

In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET

por Zhao, Ning, Bardine, Conner, Lourenço, André Luiz, Wang, Yung-hua, Huang, Yangjie, Cleary, Simon J., Wilson, David M., Oh, David Y., Fong, Lawrence, Looney, Mark R., Evans, Michael J., Craik, Charles S.
Publicado 2021

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

por Hassan, Raffit, Butler, Marcus, O’Cearbhaill, Roisin E., Oh, David Y., Johnson, Melissa, Zikaras, Kevin, Smalley, Munisha, Ross, Michael, Tanyi, Janos L., Ghafoor, Azam, Shah, Nirali N., Saboury, Babak, Cao, Liang, Quintás-Cardama, Alfonso, Hong, David
Publicado 2023

Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

por Oh, David Y., Kwek, Serena S., Raju, Siddharth S., Li, Tony, McCarthy, Elizabeth, Chow, Eric, Aran, Dvir, Ilano, Arielle, Pai, Chien-Chun Steven, Rancan, Chiara, Allaire, Kathryn, Burra, Arun, Sun, Yang, Spitzer, Matthew H., Mangul, Serghei, Porten, Sima, Meng, Maxwell V., Friedlander, Terence W., Ye, Chun Jimmie, Fong, Lawrence
Publicado 2020

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

por de Kouchkovsky, Ivan, Zhang, Li, Philip, Errol J, Wright, Francis, Kim, Daniel M, Natesan, Divya, Kwon, Daniel, Ho, Hansen, Ho, Son, Chan, Emily, Porten, Sima P, Wong, Anthony C, Desai, Arpita, Huang, Franklin W, Chou, Jonathan, Oh, David Y, Pruthi, Raj S, Fong, Lawrence, Small, Eric J, Friedlander, Terence W, Koshkin, Vadim S
Publicado 2021

Non-viral precision T cell receptor replacement for personalized cell therapy

por Foy, Susan P., Jacoby, Kyle, Bota, Daniela A., Hunter, Theresa, Pan, Zheng, Stawiski, Eric, Ma, Yan, Lu, William, Peng, Songming, Wang, Clifford L., Yuen, Benjamin, Dalmas, Olivier, Heeringa, Katharine, Sennino, Barbara, Conroy, Andy, Bethune, Michael T., Mende, Ines, White, William, Kukreja, Monica, Gunturu, Swetha, Humphrey, Emily, Hussaini, Adeel, An, Duo, Litterman, Adam J., Quach, Boi Bryant, Ng, Alphonsus H. C., Lu, Yue, Smith, Chad, Campbell, Katie M., Anaya, Daniel, Skrdlant, Lindsey, Huang, Eva Yi-Hsuan, Mendoza, Ventura, Mathur, Jyoti, Dengler, Luke, Purandare, Bhamini, Moot, Robert, Yi, Michael C., Funke, Roel, Sibley, Alison, Stallings-Schmitt, Todd, Oh, David Y., Chmielowski, Bartosz, Abedi, Mehrdad, Yuan, Yuan, Sosman, Jeffrey A., Lee, Sylvia M., Schoenfeld, Adam J., Baltimore, David, Heath, James R., Franzusoff, Alex, Ribas, Antoni, Rao, Arati V., Mandl, Stefanie J.
Publicado 2022